capecitabine-irinotecan combination

Subscribe to Selected New Research on capecitabine-irinotecan combination

2 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: a phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer 5/2007

Also Known As:

bXELIRI

Bio-Agent Context: Research Results

Therapeutics: 5195

Drug Therapy: 116609

Combination Drug Therapy: 8322

Antineoplastic Combined Chemotherapy Protocols: 16

capecitabine-irinotecan combination: 2

Antineoplastic Protocols: 20

Antineoplastic Combined Chemotherapy Protocols: 16

capecitabine-irinotecan combination: 2

Clinical Protocols

Antineoplastic Protocols: 20

Antineoplastic Combined Chemotherapy Protocols: 16

capecitabine-irinotecan combination: 2

Heterocyclic Compounds: 23

Alkaloids: 633

Camptothecin: 1048

capecitabine-irinotecan combination: 2

1-Ring Heterocyclic Compounds

Pyrimidines: 269

Pyrimidine Nucleosides: 38

Cytidine: 276

Deoxycytidine: 791

capecitabine-irinotecan combination: 2

Pyrimidinones: 13

Uracil: 876

Fluorouracil: 14197

capecitabine-irinotecan combination: 2

Nucleic Acids, Nucleotides, and Nucleosides: 1

Nucleosides: 591

Pyrimidine Nucleosides: 38

Cytidine: 276

Deoxycytidine: 791

capecitabine-irinotecan combination: 2

Deoxyribonucleosides: 28

Deoxycytidine: 791

capecitabine-irinotecan combination: 2